Balyasny Asset Management’s Cellectis CLLS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-18,352
Closed -$42K 2825
2022
Q3
$42K Buy
+18,352
New +$55.6K ﹤0.01% 2496
2018
Q1
Sell
-409,455
Closed -$11.9M 1981
2017
Q4
$11.9M Buy
409,455
+316,455
+340% +$8.62M 0.04% 575
2017
Q3
$2.65M Buy
93,000
+65,168
+234% +$1.69M 0.01% 888
2017
Q2
$719K Buy
+27,832
New +$664K ﹤0.01% 1177
2016
Q1
Sell
-57,162
Closed -$1.77M 1297
2015
Q4
$1.77M Buy
+57,162
New +$1.73M 0.01% 662

Other funds holding CLLS

Balyasny Asset Management's CLLS Position: Q4 2022 in Review

Balyasny Asset Management sold out of Cellectis (CLLS) in Q4 2022, closing a stake of 18,352 shares — an estimated $42K sold.

Balyasny Asset Management first reported a position in CLLS in Q4 2015 and held it in 5 quarters. The position peaked at $11.9M in Q4 2017. 40 funds tracked by Wall St. Rank hold CLLS as of Q4 2022.

  • Balyasny Asset Management reported no remaining Cellectis position as of Q4 2022 after selling out during the quarter.
  • Balyasny Asset Management sold 18,352 Cellectis shares in Q4 2022, an estimated $42K.
  • Balyasny Asset Management first reported a position in Cellectis in Q4 2015 and held it in 5 quarters.
  • Balyasny Asset Management's Cellectis position peaked at $11.9M in Q4 2017.
  • 40 funds tracked by Wall St. Rank held Cellectis as of Q4 2022.

Based on Balyasny Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.